J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
|
|
- Colin Hunt
- 5 years ago
- Views:
Transcription
1 VOLUME 23 NUMBER 1 JANUARY JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging Clarisse Dromain, Thierry de Baere, Jean Lumbroso, Hubert Caillet, Agnès Laplanche, Valerie Boige, Michel Ducreux, Pierre Duvillard, Dominique Elias, Martin Schlumberger, Robert Sigal, and Eric Baudin From the Department of Radiology, Institut Gustave-Roussy, Villejuif Cedex, France. Submitted January 6, 2004; accepted September 7, Authors disclosures of potential conflicts of interest are found at the end of this article. Address reprint requests to Clarisse Dromain, MD, Department of Radiology, Institut Gustave-Roussy, 39, rue Camille Desmoulins, Villejuif Cedex, France; dromain@igr.fr by American Society of Clinical Oncology X/05/ /$20.00 DOI: /JCO A B S T R A C T Purpose To compare the respective sensitivity of somatostatin receptor scintigraphy (SRS), computed tomography (CT), and magnetic resonance imaging (MRI) in the detection of liver metastases from well-differentiated gastroenteropancreatic endocrine tumor (WDGEP ET) patients. To define predictive factors for high-sensitivity SRS. Patients and Methods Sixty-four patients with WDGEP ET underwent SRS with abdominal single-photon emission computed tomography (SPECT), spiral CT, and 1.5-T MRI within a 15-day interval, the order of which was randomized. Two readers analyzed images of each modality, blindly and independently. Results Hepatic metastases were present in 40 of the 64 patients and confirmed by pathology after liver biopsy or surgery in 32 and eight patients, respectively. SRS, CT, and MRI detected a total of 204, 325, and 394 metastases, respectively. The number of detected metastases was significantly higher with MRI than with CT (P.02) and SRS (P 10 4 ) and higher with CT than with SRS (P 10 4 ). SRS was negative in seven patients with a positive CT and/or MRI. More lesions were detected in 10 patients by SPECT compared with static views. The median metastasis size was significantly correlated (P.04) with the sensitivity of SRS. Conclusion MRI seems to have an edge over CT and SRS for the detection of liver metastases from endocrine tumors. We recommend the systematic performance of liver MRI at WDGEP ET initial staging and before major therapeutic events. The low performance of SRS was mainly explained by the impact of the metastasis size on the detection capacity of SRS. J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION Well-differentiated gastroenteropancreatic (WDEGP) neuroendocrine tumors (ET), recently reclassified as endocrine tumors by the 2000 WHO classification, 1 all express specific neuroendocrine markers. They also share common clinical features including hormone secretion, their association with an inherited syndrome, and a long-term natural history in a subgroup of welldifferentiated endocrine carcinoma. The two main prognostic parameters in ET are pathological differentiation and stage. 2-5 Imaging of well-differentiated endocrine carcinoma has several goals, the more important among them being detection of the primary tumor staging and the identification of tumors forming part of the spectrum of an inherited syndrome in a subgroup of ET. 70
2 Detection of Liver Metastases In patients with gastroenteropancreatic endodermalderived ET, clinicians have taken advantage of somatostatin receptor scintigraphy (SRS) with radiolabeled octreotide, a functional imaging modality for tumor staging. SRS allows visualization of the somatostatin receptor, and especially subtype 2, which is expressed by the great majority of welldifferentiated endocrine carcinoma. 6 Introduced in 1989, SRS has led to upstaging in 10% to 43% of patients with a modification of previous therapeutic options in some cases The specificity of SRS has also been shown to be high. 12 Finally, most authors consider that SRS should be considered as a complementary conventional imaging tool in patients with ET. The presence of liver metastases as well as the degree of liver involvement are crucial to assess both prognosis and therapeutic management particularly the choice of a liver locoregional therapy like surgery, embolization, or radiofrequency. 2-5 With conventional imaging, early arterial phase imaging is important for the detection of hepatic metastases because they are highly vascularized. 13,14 In a previous computed tomography (CT) imaging study of hepatic metastases from ET, Paulson et al 13 found 30% more metastatic lesions during the arterial phase including 6% of hepatic metastasis patients exclusively evidenced on the hepatic arterial phase. We found similar results with magnetic resonance imaging (MRI) in 37 patients with liver metastases from ET. A typical hypervascular pattern was found in 73% of patients and the hepatic arterial phase MRIs revealed the greatest number of metastases in 70% of patients. 15 Standardization of conventional imaging is lacking in reported comparisons of SRS and conventional imaging techniques used to stage ET. The objective of our singlecenter prospective study was to compare the respective sensitivity of CT, MRI, and SRS in the detection of liver metastases from WDGEP ET and to define parameters influencing the sensitivity of SRS. PATIENTS AND METHODS Patients From September 2000 to October 2002, 66 consecutive patients with an endocrine tumor with or without known liver metastases were enrolled in this prospective study after referral to our institute. Inclusion criteria were confirmed WDGEP ET pathological diagnosis in our institution and absence of contraindication for CT or MRI. The liver was screened for metastases by means of CT, MRI, and SRS within a 15-day interval with randomization of the order of the three imaging modalities to avoid bias because of time effect or imaging technique interferences. Our institutional review board approved the study, and all patients gave their informed consent. MRI could not be performed in one patient because the patient did not turn up for the appointment, and CT was performed without contrast injection in one patient because of acute renal failure. These two patients were subsequently excluded from the study; therefore, a total of 64 patients (32 females and 32 males with a mean age of 57 years; range, 15 to 90 years), with a diagnosis of WDGEP ET, and who were studied with the three imaging techniques, constituted our study group. Imaging Techniques CT examinations was performed with a HiSpeed spiral scanner (GE Medical Systems, Milwaukee, WI). Spiral CT images were obtained before and after a monophasic injection of 100 ml of nonionic contrast material (Xenetix 300, Guerbet, France). A CT injector (Medrad, Pittsburgh, PA) was used to deliver contrast medium via a catheter inserted into the antecubital vein at a rate of 3 ml/sec. After injection of contrast material, three spiral CT acquisitions were obtained during the hepatic arterial phase, the portal venous phase, and the equilibrium phase at 30, 70, and 300 seconds, respectively, after the initiation of the injection. Scanning was performed at 120 kv and 270 ma. Contiguously reconstructed sections (pitch of 1:1) were obtained through the liver with 5-mm collimation. Each spiral CT acquisition through the liver was accomplished during a breath-hold. MRI examinations were performed with a 1.5-T whole-body imager (Signa LX; General Electric Medical Systems, Milwaukee, WI). All MRIs were acquired in the axial plane with a phased-array body multicoil. Slice thickness was 7 mm, with a 2-mm intersection gap for all pulse sequences. Fat-suppressed T2-weighted imaging was obtained with a respiratory-triggered fast spin-echo sequence (4,000 to 8,000/102): effective TR/effective TE, 16 echo train length, four signals acquired, 10-millisecond interecho spacing, matrix, khz received bandwidth, 280 to 400 mm field of view, 20% respiratory trigger point, 40% trigger window, and gradient moment nulling in the frequency-encoding direction. Saturation bands above and below the imaging volume were used to attenuate flow-related artifacts throughout MRI. Breath-hold single-shot fast spin-echo sequences were obtained using the following parameters: /90 (effective TR/effective TE), half-fourier acquisition, 104 echo train length, one signal acquired, matrix, 62.5 khz received bandwidth, and 40-cm field of view. Dynamic contrast-enhanced MRIs were obtained with an initial delay of 10 seconds and then at three consecutive 30-second intervals and 5 minutes after the initiation of a bolus injection of 0.1 mmol/kg of Gd-DOTA (Dotarem, Guerbet, France) into the antecubital vein. T1-weighted sequences were acquired with fast multiplanar spoiled gradient-recalled echo imaging (125/4.2) TR/TE, 60 degrees flip angle, one signal acquired, matrix, 62.5 khz received bandwidth, 40-cm field of view, and 25-second acquisition time in a single breath-hold. SRS was performed after intravenous injection of Indium-111- DTPA-Phe1-octreotide (pentetreotide; OctreoScan; Mallinckrodt Medical, Petten, the Netherlands; 170 to 220 MBq). Using the dedicated kit containing the In-111 chloride solution and a special needle, quality control revealed a labeling yield of more than 98% for this radiopharmaceutical. To reduce digestive artifacts, an adequate colonic preparation was administered (64 g of macrogol 4000 in the evening after the injection and again the next morning before 24-hour imaging). A large field-of-view gamma camera equipped with a medium-energy collimator was used (Axis double detector gamma camera; Philips Medical Systems, Best, the Netherlands). Acquisition was performed using both 111 In photopeaks (171 and 245 kev). As recommended, 16 static anterior and posterior spot views covering the whole body ( word matrix, at least 10 minutes per view or 300,000 preset counts for the head and neck and 500,000 for the rest of the body), were acquired at 4 hours, 24 hours, and when needed, at
3 Dromain et al hours. Abdominal single-photon emission computed tomography (SPECT) was performed at 24 hours with 64 projections ( word matrix, 1 minute per projection) and iterative reconstruction. An additional thoracic SPECT was performed when necessary. Image Analysis Images of each modality were analyzed by two readers (radiologists and nuclear physicians) per modality, blindly and independently. CTs and MRIs were all interpreted on a digital workstation (Pathspeed; General Electric Medical Systems, Milwaukee, WI), with total freedom for window and level adjustments and for the magnification of each image at the time of the analysis. SRS images were analyzed on films. Radiologists and nuclear physicians were unaware of clinical and biological findings or of any imaging studies concerning the patients. They knew, however, that all patients had an endocrine tumor and were being examined to evaluate the presence and extent of hepatic metastases. The six readers scored the number of metastases depicted at each examination. Only presumed metastatic lesions for which the confidence rate was high were taken into account. A patient was considered positive for one liver imaging modality when at least one liver lesion meeting the malignancy criteria was depicted in agreement with both observers and at least one typical lesion was discovered on biopsy to confirm the WDGEP ET liver metastasis diagnosis. A patient was considered negative when no liver lesion meeting the malignancy criteria was depicted in agreement with both observers. In this study, the terms positive and negative refer to the liver status. All images of each imaging modality were taken into account to establish the presence or absence and the number of hepatic metastases. When more than 15 metastases were depicted, 16 were considered for the statistical analysis. The final number of metastases for each modality, determined by the consensus of two readers, was obtained during a second reading session. The size, location (made segment by segment according to the Couinaud numbering system with drawing), and the pattern of enhancement of each metastasis were also noted for CT and MRI. For SRS, only the total number of lesions was taken into account. All patients with presumed liver metastases detected with at least one imaging modality experienced either a biopsy (n 32) or a surgery (n 8). To assess a relative sensitivity of each imaging modality: (1) we arbitrarily set the total number of liver metastases by summing the number of metastases depicted for each patient by the highest sensitive modality (reference number), (2) we calculated the ratio between the total number of metastases determined by each modality to the reference number. The extrahepatic tracer uptake was also recorded for SRS. A specific analysis of the group of patients treated with the somatostatin analog at the time of the imaging protocol was also performed. Statistical Analysis To assess interobserver agreement in interpreting images, the statistic was used to measure the degree of agreement between the two observers for each imaging technique. A value attaining 0.40 signified positive but poor agreement, a value of 0.41 to 0.75 indicated good agreement, and a value exceeding 0.75 indicated excellent agreement. Wilcoxon s signed-rank test was used for the statistical analysis of the number of metastases detected by each imaging technique and a P value of less than.05 was considered significant. To define parameters influencing the relative sensitivity of SRS, two groups of patients were compared using the 2 test: patients in the high-sensitivity SRS group had a difference of less than 5 in the number of liver metastases detected with SRS and the best imaging modality whereas patients in the low-sensitivity SRS group had false-negative SRS results or a difference of 5 or more liver metastases detected with SRS and the best imaging modality. Parameters taken into account for this analysis were sex and age, the primary tumor site, the absence or presence of hormonal secretion, previous surgical removal of the primary tumor, the median size of metastases on the morphological examination that detected the higher number of metastases, and the pattern of enhancement of hepatic metastases on CT and MRI. RESULTS Patients Patients characteristics and results are summarized in Table 1. Primary ET sites were the small bowel (n 21), pancreas (n 15), lung (n 11), colon and rectum (n 3), unknown (n 5), appendix (n 3), thymus (n 2), duodenum (n 2), larynx (n 1), and esophagus (n 1). Multiple endocrine neoplasia (MEN) type 1 was present in two patients with a pancreatic tumor. Hormonal secretion was present in 37 (59%) patients, including four clinically functioning pancreatic ET (one insulinoma, one gastrinoma, two glucagonoma). Fourteen patients were screened for the initial diagnosis and staging of the primary tumor whereas 50 patients were being investigated during follow-up. Twenty-six patients had previously received treatment including systemic chemotherapy (n 19), somatostatin analogs (n 5), and interferon (n 1). Only 13 patients were treated at the time of the imaging protocol with somatostatin analogs in 12 patients and chemotherapy in one patient. Interobserver Agreement Interobserver agreement was excellent for MRI and CT with a value of 84% and 78%, respectively, and was good for SRS with a value of 69%. SRS discrepant results between observers refer to the number of liver metastases at abdominal SPECT in all patients but one. Liver Imaging Results Of the 64 consecutive patients with a diagnosis of ET eligible in the study, 40 patients (62.5%) had hepatic metastasis detected by at least one imaging modality (Fig 1). The total number of metastases detected on SRS, CT, and MRI was 204, 325, and 394 in 33, 39, and 39 patients, respectively (Table 2). MRI detected significantly more liver metastases than CT (P.02) and SRS (P 10 4 ), and CT detected significantly more liver metastases than SRS (P 10 4 ). The relative sensitivities of SRS, CT, and MRI were 49.3%, 78.5%, and 95.2%, respectively. Based on a per-patient analysis, the maximum number of metastases was found with MRI in 14 patients (35%), with CT in six patients (15%), and with SRS in one patient (2.5%). When imaging modalities were analyzed, CT was negative in two patients (5%) with a positive SRS and in one patient (2.5%) with a positive MRI (Fig 2). MRI was 72 JOURNAL OF CLINICAL ONCOLOGY
4 Detection of Liver Metastases Patient No. Table 1. Individual Characteristics of 64 Patients With Well-Differentiated Endocrine Tumors Age (years) Sex Primary Hormonal Secretion Liver Metastases No. of Metastases SRS CT MRI 1 75 F Lung 0 Y M Unknown CgA, calcitonin Y M Pancreas Calcitonin N F Ileum 5HIAA Y F Pancreas Insulin Y M Thymus ACTH, CgA Y F Unknown 0 Y F Unknown CgA N M Lung 0 N F Ileum 0 Y F Duodenum CgA Y F Larynx Calcitonin N F Rectum 0 Y M Ileum 0 N M Appendix 0 N M Pancreas CgA N M Pancreas Gastrin Y M Ileum 5HIAA Y F Ileum 0 N F Ileum 5HIAA Y M Ileum 5HIAA, CgA Y M Pancreas CgA N F Colon 0 Y M Ileum 0 Y F Ileum CgA Y F Lung 0 Y M Pancreas CgA N M Lung CgA, 5HIAA Y F Ileum 5HIAA Y M Unknown 0 N F Pancreas Glucagon Y M Lung 0 N F Duodenum 0 N F Ileum 0 Y F Appendix 0 N F Ileum CgA, 5HIAA Y M Pancreas 0 Y M Lung CgA, 5HIAA Y M Ileum CgA, 5HIAA Y F Ileum CgA, 5HIAA Y M Ileum CgA, 5HIAA N F Ileum CgA N F Ileum 0 Y F Pancreas 0 Y F Pancreas CgA Y F Lung CgA, 5HIAA Y F Lung 0 N F Ileum CgA N M Pancreas 0 N M Pancreas 0 Y M Lung Calcitonin, CgA Y F Unknown CgA Y M Pancreas 0 Y F Ileum 5HIAA Y M Esophagus 5HIAA N M Pancreas Glucagon, CgA Y F Rectum 0 N M Ileum 5HIAA Y M Ileum CgA, 5HIAA Y M Appendix 0 N F Lung 0 N M Thymus CgA N M Pancreas Calcitonin, CgA Y M Lung 0 Y Abbreviations: SRS, somatostatin receptor scintigraphy; CT, computed tomography MRI, magnetic resonance imaging; F, female; M, male; Y, yes; N, no; CgA, Chromogranin A; 5HIAA, 5 hydoxyindolacetic acid; ACTH, corticotropin. When more than 15 metastases were depicted, 16 were considered for the statistical analysis. 73
5 Dromain et al Fig 1. Liver screening in a 50-year-old man with an ileum endocrine tumor. (A) Enhanced computed tomography, (B) unenhanced T2-weighted magnetic resonance imaging (MRI), and (C) arterial phase-enhanced T1-weighted MRIs demonstrated a typical pattern of hypervascular metastases, also well shown on (D) axial tomographies of somatostatin receptor scintigraphy. negative in a patient with a positive SRS. SRS failed to detect hepatic metastases in seven patients (17.5%) in whom MRI or CT was positive for hepatic metastases. In the 12 patients treated with somatostatin analogs, SRS was positive in nine with positive CT and MRI results and negative in three patients with negative CT and MRI results. The number of liver metastases detected in the nine patients with positive findings was 55, 94, and 94 on SRS, CT, and MRI, respectively. None of these 12 patients experienced an objective response with somatostatin analog therapy. Table 2. Number of Metastases According to Imaging Modalities Reviewer 1 Reviewer 2 Consensus CT MRI SRS Abbreviations: CT, computed tomography; MRI, magnetic resonance imaging; SRS, somatostatin receptor scintigraphy. The median size of depicted metastases was 12 mm for CT and 10.5 for MRI. Metastases were hypervascular in 30 patients (77%) and hypovascular in nine patients (23%) at both CT and MR imaging. A miliary pattern with numerous small hepatic lesions scattered throughout the liver was present in nine patients (22.5%; Fig 3). Among the 204 metastases detected on SRS, 190 were detected on static anterior and posterior views whereas 203 metastases were detected on abdominal SPECT. Abdominal SPECT increased the number of metastases detected with SRS in 10 patients in whom 13 additional lesions had not been detected with the static views. SRS also detected extrahepatic tracer uptake in 32 patients (51%). Predictors of High-Sensitivity SRS The median size of metastases was the only factor significantly correlated with the sensitivity of SRS for the detection of liver metastases (P.04). Indeed, a positive SRS classified as a high-sensitivity SRS result was found in 22% of patients with a median metastasis size of less than 7 mm, in 35% of patients with a median metastasis size of 8 to 14 mm, and 64% of patients with a median metastasis size of 74 JOURNAL OF CLINICAL ONCOLOGY
6 Detection of Liver Metastases Fig 2. Liver screening in a 29-year-old woman with pancreatic insulinoma. (A) Arterial and (B) portal phase-enhanced computed tomography images show no obvious metastases whereas (C and D) arterial phase-enhanced magnetic resonance imaging shows several hypervascular metastases. (E) Somatostatin receptor scintigraphy planar view is falsely negative. more than 15 mm (Table 3). A trend was seen toward better sensitivity of SRS in the detection of liver metastases when the primary tumor was located in the ileum compared with primary tumors located in the lung but the difference was not statistically significant (Table 4). No significant difference was found in the sensitivity of SRS between metastases 75
7 Dromain et al Fig 3. Liver screening in a 70-year-old man with an unknown endocrine tumor. (A) Arterial phase-enhanced computed tomography image shows minute contrast uptake disappearing on (B) portal phase image. (C) T2-weighted magnetic resonance imaging demonstrates metastatic hepatic miliary well. (D) Axial tomographies of somatostatin receptor scintigraphy was falsely negative. classified as hypovascular and hypervascular nor between biologically functional and nonfunctional tumors. DISCUSSION Controversy persists regarding the most accurate diagnostic method for the detection of hepatic metastases from ET 10,11,16,17 To our knowledge, our study is the first to compare prospectively three standardized imaging modalities for the detection of WDGEP ET metastases to the liver. Indeed, in most studies comparing conventional imaging and SRS, the parameters of the imaging technique used were not specified, namely the performance of either CT or MRI during the arterial phase after injection of contrast medium. Moreover, in our study, each imaging modality was performed within a short time period, according to the Table 3. Correlation Between the Sensitivity of SRS and the Median Size of Metastases Median Size of Metastases High- Sensitivity SRS Low- Sensitivity SRS Total No. % No. % No. % 7 mm mm mm Total Abbreviation: SRS, somatostatin receptor scintigraphy. Table 4. Correlation Between the Sensitivity of SRS and the Primary Tumor Site Primary Tumor High- Sensitivity SRS Low- Sensitivity SRS Total No. % No. % No. % Lung Pancreas-duodenum Ileum Miscellaneous Total Abbreviation: SRS, somatostatin receptor scintigraphy. 76 JOURNAL OF CLINICAL ONCOLOGY
8 Detection of Liver Metastases same protocol for each patient and was in keeping with current methodological recommendations. The results of this study highlight the superiority of MRI over CT and SRS in the detection of hepatic metastases from ET. MRI detected 190 hepatic metastases missed by SRS and 69 missed by CT. Based on a per-patient analysis, liver uptake was negative in 17.5% of patients with SRS whereas CT and MRI results were positive. CT and MRI results were negative when SRS was positive in only one patient with one hepatic metastasis. MRI depicted a far greater number of liver metastases than CT despite its lower spatial resolution and even when liver metastases exhibited a miliary pattern. This is probably due to the high-contrast resolution of MRI, especially on T2- weighted images and on the hepatic arterial phase enhanced T1-weighted images. 15 Standardization of imaging techniques is a key point of the sensibility, of both CT and MR imaging, in the detection of liver metastases from WDGEP ET. Indeed, as already mentioned, the arterial phase plays a major role to standardize the detection of endocrine liver metastases and must be systematically performed during CT and MR imaging in both initial and follow-up screening. On MRI, we also recommend performance of two T2-weighted sequences: one with a high lesion-to-liver contrast-noise ratio for solid lesion (fast spin-echo sequence) and another with high contrast for tissues with a long T2 relaxation time (single-shot sequence). The first has a high sensibility in the detection of liver metastases, whereas the second has a high specificity allowing optimal distinction between hypervascular metastases from hemangiomas. 15 Therefore, we advocate liver MRI as a critical tool in patients with WDGEP ET. Our practical recommendation is to systematically perform a liver MRI, and not a CT, in the initial and preoperative screening of metastatic spread in WDGEP ET patients. MRI plays a major role in detecting liver metastases whereas SRS may play a complementary role in detecting extrahepatic disease as claimed by other studies It is also our personal experience that liver MRI should be performed during a patient s follow-up examination. Indeed, unenhanced MRIs such as unenhanced T1- weighted and unenhanced T2-weighted images allow a good detection and delineation of liver metastases and have the advantage over enhanced CT or MR images to be reproducible with time because they are not influenced by the uptake of contrast agent, variable with the physiological conditions. Taking into account the cost of MRI compared with CT, however, a practical recommendation during follow-up would be to evaluate the patient with WDGEP ET liver with both techniques first and then to choose the most accurate. These results are at variance with one study comparing MRI and CT in the detection of liver metastases in 24 patients with gastrinoma. 10 In that study, SRS was the most sensitive liver imaging method compared with any of the conventional imaging methods. SRS results found in gastrinoma patients, therefore, may not be applicable to other gastroenteropancreatic ET. The high frequency of positive subtype 2 somatostatin immunoreactivity in gastrinoma compared with other gastroenteropancreatic tumors may partly explain these discrepancies. 18 The only parameter significantly associated with high-sensitivity SRS was the median size of metastases. This result has already been reported for the detection of primary gastrinoma arising in the duodenum and pancreas. 19 The size effect could be caused by the amount of radionuclide uptake required for detection, as suggested when different radionuclides were used. 19 The type or density of the somatostatin receptors expressed by the tumor may be a predominant additional factor. The recent somatostatin analog radionuclide with improved subtype 2 receptor affinity but also great internalization properties may overcome these drawbacks. 20,21 These new somatostatin radiolabeled compounds, tailored for positron imaging technology, hold great promise for an enhancement of the sensitivity of SRS Conversely, 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography is of limited value for the imaging of well-differentiated endocrine tumors. 25 With regard to SRS acquisition methods and in agreement with previous reports, our study confirms that SPECT is more sensitive for the detection of focal lesions than planar imaging. 17 SPECT is endowed with the capacity to display cross-sectional images and has better contrast resolution than planar imaging, which accounts for its enhanced sensitivity. Despite the poor performance of SRS in the present study, its specificity is reported to be high at 88%. 12 Furthermore, SRS explores the total body and could be useful for the selection of patients for somatostatin analogs, radiolabeled somatostatin analog therapy, or probe-guided surgery. Finally, contrary to previous studies where SRS showed a greater likelihood of being positive in patients with elevated 5HIAA, we found no correlation between the performance of SRS and the presence of hormonal secretion 26 There are, however, several limitations in our study. First, although ET-derived liver metastases were pathologically proven in all patients, a detailed lesion-bylesion pathological analysis was not possible because most of the patients in this series had advanced metastatic ET to the liver and, therefore, were not submitted to hepatic resection. This must be taken into account in the interpretation of the relative sensitivities of the three imaging techniques. A second potential limitation is that 12 patients were treated during the imaging protocol with somatostatin analogs that could have affected the performance of SRS. Indeed, it has been suggested that somatostatin analogs may result in low or no uptake of the radioligand because of occupancy, competition, or 77
9 Dromain et al downregulation of the receptors by the unlabeled ligand. However, subsequent studies have shown that somatostatin analog treatment modifies the biodistribution of 111 Inpentetreotide, significantly increasing the tumor-tobackground ratio In our study, no patient treated with somatostatin analogs at the time of imaging had positive CT and MRI when the SRS result was negative. The number of liver metastases detected by SRS in this group of treated patients was lower than the number of metastases detected by CT and MRI but with a similar difference to that found in the group of untreated patients. Thus, somatostatin analog therapy does not seem to have had a great influence on the performance of SRS. Finally, specificity could not be evaluated because a liver biopsy was not performed in patients with negative liver imaging. In conclusion, MRI depicted by far the greatest number of hepatic metastases in patients with WDGEP ET. This imaging modality, therefore, appears to be the procedure of choice for initial staging and liver evaluation before surgery, embolization, or radiofrequency in patients with ET. The low performance of SRS was mainly explained by the effect of the size of liver metastases on its detection capacity. Acknowledgment We thank Lorna Saint Ange for editing. Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. REFERENCES 1. Solcia EKG, Sobin LH. Histological typing of endocrine tomours, in Springer (ed): WHO Classification, International Histological Classification of Tumours (ed 2). Berlin, Germany, Springer, Madeira I, Terris B, Voss M, et al: Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43: , Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8: , Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E: Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis, pathology, and behavior. World J Surg 20: , Yu F, Venzon DJ, Serrano J, et al: Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17: , Hofland LJ, Lamberts SW, van Hagen PM, et al: Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D- Phe1]octreotide in somatostatin receptor-positive organs. J Nucl Med 44: , Westlin JE, Janson ET, Arnberg H, Ahlstrom H, Oberg K, Nilsson S: Somatostatin receptor scintigraphy of carcinoid tumours using the [111In- DTPA-D-Phe1]-octreotide. Acta Oncol 32: , Scherubl H, Bader M, Fett U, et al: Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 105: , Jamar F, Fiasse R, Leners N, Pauwels S: Somatostatin receptor imaging with indium-111- pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management. J Nucl Med 36: , Gibril F, Reynolds JC, Doppman JL, et al: Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas A prospective study. Ann Intern Med 125: 26-34, Chiti A, Fanti S, Savelli G, et al: Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-enteropancreatic tumours. Eur J Nucl Med 25: , Gibril F, Reynolds JC, Chen CC, et al: Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 40: , Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC: Carcinoid metastases to the liver: Role of triple-phase helical CT. Radiology 206: , Foley WD, Mallisee TA, Hohenwalter MD, Wilson CR, Quiroz FA, Taylor AJ: Multiphase hepatic CT with a multirow detector CT scanner. AJR Am J Roentgenol 175: , Dromain C, de Baere T, Baudin E, et al: MR imaging of hepatic metastases caused by neuroendocrine tumors: Comparing four techniques. AJR Am J Roentgenol 180: , Kwekkeboom DJ, Krenning EP: Somatostatin receptor scintigraphy in patients with carcinoid tumors. World J Surg 20: , Schillaci O, Spanu A, Scopinaro F, et al: Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 44: , Kulaksiz H, Eissele R, Rossler D, et al: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50:52-60, Alexander HR, Fraker DL, Norton JA, et al: Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 228: , de Jong M, Breeman WA, Bakker WH, et al: Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58: , Reubi JC, Schar JC, Waser B, et al: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27: , Hofmann M, Maecke H, Borner R, et al: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 28: , Kwekkeboom DJ, Bakker WH, Kam BL, et al: Treatment of patients with gastroentero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 30: , Wester HJ, Schottelius M, Scheidhauer K, et al: PET imaging of somatostatin receptors: Design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 30: , Adams S, Baum R, Rink T, Schumm- Drager PM, Usadel KH, Hor G: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79-83, Kalkner KM, Janson ET, Nilsson S, Carlsson S, Oberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers. Cancer Res 55: , 1995 (suppl) 27. Dorr U, Rath U, Sautter-Bihl ML, et al: Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 20: , Janson ET, Kalkner KM, Eriksson B, Westlin JE, Oberg K: Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. Nucl Med Biol 26: , Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S: Indium-111-pentetreotide uptake in endocrine tumors and lymphoma. J Nucl Med 37: , Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW: Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide. Endocrinology 136: , JOURNAL OF CLINICAL ONCOLOGY
MR Imaging of Hepatic Metastases Caused by Neuroendocrine Tumors: Comparing Four Techniques
Clarisse Dromain 1 Thierry de Baere 1 Eric Baudin 2 Joel Galline 1 Michel Ducreux 3 Valérie Boige 3 Pierre Duvillard 4 Agnès Laplanche 5 Hubert Caillet 1 Philippe Lasser 6 Martin Schlumberger 2 Robert
More informationOriginal article. M. Cimitan 1 *, A. Buonadonna 2, R. Cannizzaro 3, V. Canzonieri 4, E. Borsatti 1, R. Ruffo 1 & L. De Apollonia 5.
Original article Annals of Oncology 14: 1135 1141, 2003 DOI: 10.1093/annonc/mdg279 Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors
More informationImaging of Neuroendocrine Metastases
Imaging of Neuroendocrine Metastases Aoife Kilcoyne, Shaunagh McDermott, Colin McCarthy,Manuel Patino, Dushyant Sahani, Michael Blake Abdominal Imaging Division Massachusetts General Hospital Disclosure
More informationGallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study
Nuclear Medicine and Molecular Imaging Original Research Naswa et al. PET/CT of Gastroenteropancreatic NETs Nuclear Medicine and Molecular Imaging Original Research Niraj Naswa 1 Punit Sharma 1 Abhishek
More informationSurgical treatment of neuroendocrine metastases
Best Practice & Research Clinical Gastroenterology Vol. 19, No. 4, pp. 577 583, 2005 doi:10.1016/j.bpg.2005.04.003 available online at http://www.sciencedirect.com 6 Surgical treatment of neuroendocrine
More informationDiagnosing and monitoring NET
Diagnosing and monitoring NET Inaccurate or delayed diagnosis of neuroendocrine tumors (NET) is common, because many NET are small and asymptomatic. 1 When symptoms are present, they are usually nonspecific
More informationImaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear
Imaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear Eric Tamm, M.D. Department of Diagnostic Radiology Division of Diagnostic Imaging MD Anderson Cancer Center Houston, TX Disclosure
More informationInternational Journal of Current Medical Sciences- Vol. 6, Issue,, pp , June, 2016 A B S T R A C T
ISSN: 2320-8147 International Journal of Current Medical Sciences- Vol. 6, Issue,, pp. 122-126, June, 2016 COMPUTED TOMOGRAPHY IN HEPATIC METASTASES Ananthakumar P and Adaikkappan M., Available online
More informationNuclear oncology using SPECT and PET is able to show
Molecular Imaging as In Vivo Molecular Pathology for Gastroenteropancreatic Neuroendocrine Tumors: Implications for Follow-Up After Therapy Eric P. Krenning, MD, PhD 1,2 ; Roelf Valkema, MD, PhD 1 ; Dik
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationFalse-Positive Somatostatin Receptor Scintigraphy: Really?
Logo False-Positive Somatostatin Receptor Scintigraphy: Really? Dr. Augusto Llamas-Olier, Dr. Maria Cristina Martinez, Dr. Emperatriz Angarita, Dr. Amelia De Los Reyes Nuclear medicine department. Instituto
More informationColor Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging
Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:
More informationLutetium-DOTA TATE Treatment of inoperable GEP NETs
Logo 177 Lutetium-DOTA TATE Treatment of inoperable GEP NETs Dr. Augusto Llamas-Olier. Nuclear medicine department. Dr. Maria Cristina Martínez*, Dr. Alfonso Lozano** and Dr. Augusto Llamas-Olier*. *Nuclear
More informationStaging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy
Original article Annals of Oncology 14: 586 591, 2003 DOI: 10.1093/annonc/mdg160 Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy F. Panzuto
More informationGastrinoma: Medical Management. Haley Gallup
Gastrinoma: Medical Management Haley Gallup Also known as When to put your knife down Gastrinoma Definition and History Diagnosis Historic Management Sporadic vs MEN-1 Defining surgical candidates Nonsurgical
More informationIndex. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 15 (2006) 681 685 Index Note: Page numbers of article titles are in boldface type. A Ablative therapy, for liver metastases in patients with neuroendocrine tumors, 517 with radioiodine
More informationPeptide Receptor Radionuclide Therapy using 177 Lu octreotate
Peptide Receptor Radionuclide Therapy using 177 Lu octreotate BLR Kam, Erasmus Medical Centre, Rotterdam DJ Kwekkeboom, Erasmus Medical Centre, Rotterdam Legal aspects As 177 Lu-[DOTA 0 -Tyr 3 ]octreotate
More informationThe Frequency and Significance of Small (15 mm) Hepatic Lesions Detected by CT
535 Elizabeth C. Jones1 Judith L. Chezmar Rendon C. Nelson Michael E. Bernardino Received July 22, 1991 ; accepted after revision October 16, 1991. Presented atthe annual meeting ofthe American Aoentgen
More informationPNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.
GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationTargeted Radionuclide Therapy with 90 Y-DOTATOC in Patients with Neuroendocrine Tumors
Targeted Radionuclide Therapy with 90 Y-DOTATOC in Patients with Neuroendocrine Tumors FLAVIO FORRER 1, CHRISTIAN WALDHERR 1, HELMUT R. MAECKE 2 and JAN MUELLER-BRAND 1 1 Institute of Nuclear Medicine
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.
More informationNeuroendocrine Tumors
Neuroendocrine Tumors Neuroendocrine tumors arise from cells that release a hormone in response to a signal from the nervous system. Neuro refers to the nervous system. Endocrine refers to the hormones.
More informationHEPATIC METASTASES. We can state 3 types of metastases depending on their treatment options:
HEPATIC METASTASES 1. Definition Metastasis means the spread of cancer. Cancerous cells can separate from the primary tumor and enter the bloodstream or the lymphatic system (the one that produces, stores,
More informationAppendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer
Appendix 1: Regional Lymph Node Stations for Staging Esophageal Cancer Locoregional (N stage) disease was redefined in the seventh edition of the AJCC Cancer Staging Manual as any periesophageal lymph
More informationCase Report. Ameya D. Puranik, MD, FEBNM; Harshad R. Kulkarni, MD; Aviral Singh, MD; Richard P. Baum, MD, PhD ABSTRACT
Case Report 8-YEAR SURVIVAL WITH A METASTATIC THYMIC NEUROENDOCRINE TUMOR: EMPHASIS ON REDEFINING TREATMENT OBJECTIVES USING PERSONALIZED PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 177 Lu- AND 90 Y-LABELED
More informationCase Report Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog
Case Reports in Endocrinology Volume 2013, Article ID 252159, 4 pages http://dx.doi.org/10.1155/2013/252159 Case Report Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog Ricardo Costa,
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationMolecular Imaging Guided Therapy: The Perfect Storm. David M Schuster, MD Emory University Department of Radiology Atlanta, GA
Molecular Imaging Guided Therapy: The Perfect Storm David M Schuster, MD Emory University Department of Radiology Atlanta, GA Talk can be found at radiology.emory.edu Let s start with a case 74 year
More informationPrinciples of nuclear metabolic imaging. Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium
Principles of nuclear metabolic imaging Prof. Dr. Alex Maes AZ Groeninge Kortrijk and KULeuven Belgium I. Molecular imaging probes A. Introduction - Chemical disturbances will precede anatomical abnormalities
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationRadiology Pathology Conference
Radiology Pathology Conference Nadia F. Yusaf, M.D. PGY-3 1/29/2010 Presentation material is for education purposes only. All rights reserved. 2010 URMC Radiology Page 1 of 90 Case 1 60 year- old man presents
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationNuclear Medicine and PET. D. J. McMahon rev cewood
Nuclear Medicine and PET D. J. McMahon 150504 rev cewood 2018-02-15 Key Points Nuclear Medicine and PET: Imaging: Understand how Nuc Med & PET differ from Radiography & CT by the source of radiation. Be
More informationCase Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors
Case Presentation Marianne Ellen Pavel Charité University Medicine Berlin ESMO Preceptorship on GI Neuroendocrine Tumors Session 3; Singapore November 2, 2012 06.11.2012 Medical History 46-year-old man
More informationAnatomical and Functional MRI of the Pancreas
Anatomical and Functional MRI of the Pancreas MA Bali, MD, T Metens, PhD Erasme Hospital Free University of Brussels Belgium mbali@ulb.ac.be Introduction The use of MRI to investigate the pancreas has
More informationFDG-PET value in deep endometriosis
Gynecol Surg (2011) 8:305 309 DOI 10.1007/s10397-010-0652-6 ORIGINAL ARTICLE FDG-PET value in deep endometriosis A. Setubal & S. Maia & C. Lowenthal & Z. Sidiropoulou Received: 3 December 2010 / Accepted:
More informationManagement of Pancreatic Islet Cell Tumors
Management of Pancreatic Islet Cell Tumors Ravi Dhanisetty, MD November 5, 2009 Morbidity and Mortality Conference Case Presentation 42 yr female with chronic abdominal pain. PMHx: Uterine fibroids Medications:
More informationSpecialised Services Policy CP66: 68-gallium DOTA- peptide scanning for the Management of Neuroendocrine Tumours (NETs)
Specialised Services Policy CP66: Management of Neuroendocrine Tumours (NETs) Document Author: Assistant Planner for Cancer and Blood Executive Lead: Director of Quality and Nursing Approved by: Management
More informationMany human tumors are known to express somatostatin
An Intrapatient Comparison of Tc-EDDA/ HYNIC-TOC with In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor Expressing Tumors Michael Gabriel, MD 1 ; Clemens Decristoforo, PhD 1 ; Eveline Donnemiller,
More informationImaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear
Imaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear Eric Tamm, M.D. Department of Diagnostic Radiology Division of Diagnostic Imaging MD Anderson Cancer Center Houston, TX Disclosure
More informationClinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience
Endocrine-Related Cancer (2009) 16 977 990 Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience S Scigliano 1, R Lebtahi 1, F Maire
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationFunctional Anatomical Image Fusion in Neuroendocrine Tumors
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS Volume 19, Number 1, 2004 Mary Ann Liebert, Inc. Functional Anatomical Image Fusion in Neuroendocrine Tumors Orazio Schillaci Department of Diagnostic Imaging,
More informationPET/MR:Techniques, Indications and Applications
PET/MR:Techniques, Indications and Applications Franz Wolfgang Hirsch Professor and Head of the Department of Pediatric Radiology University Hospital Leipzig / Germany Children s Hospital University Leipzig
More informationCase Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results
Case Reports: Tumor Detection by Diffusion-Weighted MRI and ADC-Mapping with Correlation to PET/CT Results Matthias Philipp Lichy, M.D.; Philip Aschoff, M.D.; Christina Pfannenberg, M.D.; Schlemmer Heinz-Peter,
More informationNeuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear
More informationNEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS
University of Miami Jackson Memorial Hospital Role of the Surgeon in the Approach to Neuroendocrine tumors Dido Franceschi, MD Professor of Surgery University of Miami Karzinoide Siegfried Oberndorfer,
More informationGemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis
GE Healthcare Gemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis CT clinical case study lesion characterization Desiree Morgan, MD Vice Chair of Clinical Research Professor
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationIndex. radiologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACC. See Adrenal cortical carcinoma. Acromegaly and the pituitary gland, 551 Acute suppurative thyroiditis, 405, 406 Addison, Thomas and
More informationNeuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam
Neuro-endocrine and pancreatic non-adenocarcinomas Marc Engelbrecht, AMC, Amsterdam Pancreatic Tumors q Epithelial Exocrine q Mesenchymal Ductal Adenocarcinoma (85-95%) Metastasis Lymfoma Acinar Cell Carcinoma
More informationGeneral summary GENERAL SUMMARY
General summary GENERAL SUMMARY In Chapter 2.1 the long-term results and prognostic factors of radiofrequency ablation (RFA) for unresectable colorectal liver metastases (CRLM) in a single center with
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationAccepted Preprint first posted on 12 February 2013 as Manuscript ERC
Page 1 of 28 Accepted Preprint first posted on 12 February 2013 as Manuscript ERC-12-0169 Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high grade of uptake
More informationWell-differentiated gastro-entero-pancreatic endocrine
ORIGINAL ARTICLE Endocrine Care Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging
More informationNuclear medicine studies of the digestiv system. Zámbó Katalin Department of Nuclear Medicine
Nuclear medicine studies of the digestiv system Zámbó Katalin Department of Nuclear Medicine Anatomy of the liver Liver scintigraphy The labelled colloid (200 MBq 99mTc-Fyton) is phagocyted by the Kuppfer-cells
More informationPreliminary Report on Somatostatin Receptor Imaging in Rare Endocrine Tumours
ORIGINAL ARTICLE Preliminary Report on Somatostatin Receptor Imaging in Rare Endocrine Tumours BJJ Abdullah, FRCR*, M Paramsothy, FRCP**, AS M Khir, FRCP**, S P Chan, MRCP**, *Department ofradiology, **DepartmentofMedicine,
More informationSurgical Therapy of GEP-NET: An Overview
Surgical Therapy of GEP-NET: An Overview Pierce K.H Chow MBBS, MMed, FRCSE, FAMS, PhD Professor, Duke-NUS Graduate School of Medicine Senior Consultant Surgeon, Singapore General Hospital Visiting Senior
More informationAn Introduction to PET Imaging in Oncology
January 2002 An Introduction to PET Imaging in Oncology Janet McLaren, Harvard Medical School Year III Basics of PET Principle of Physiologic Imaging: Allows in vivo visualization of structures by their
More informationGastrointestinal tract
Gastrointestinal tract Colloidal liver-spleen imaging Presented by: Jehad Felemban Introduction: To obtain better anatomic display of liver and spleen architecture, we use (CT Ultrasound). (Radionuclide
More informationMRI Abdomen Protocol Pancreas/MRCP with Contrast
MRI Abdomen Protocol Pancreas/MRCP with Contrast Reviewed By: Brett Mollard, MD; Anna Ellermeier, MD Last Reviewed: July 2018 Contact: (866) 761-4200 Standard uses: 1. Characterization of cystic and solid
More informationMR Advance Techniques. Vascular Imaging. Class II
MR Advance Techniques Vascular Imaging Class II 1 Vascular Imaging There are several methods that can be used to evaluate the cardiovascular systems with the use of MRI. MRI will aloud to evaluate morphology
More informationChapter 23 Clinical Efficacy of PET/CT Using
Chapter 23 Clinical Efficacy of PET/CT Using 68 Ga-DOTATOC for Diagnostic Imaging Yuji Nakamoto, Takayoshi Ishimori, and Kaori Togashi Abstract Positron emission tomography/computed tomography (PET/CT)
More informationDiabetes mellitus and its effects on all cause mortality after radiopeptide therapy for neuroendocrine tumors
Journal of Nuclear Medicine, published on September 15, 2016 as doi:10.2967/jnumed.116.180687 Diabetes mellitus and its effects on all cause mortality after radiopeptide therapy for neuroendocrine tumors
More informationMedical imaging X-ray, CT, MRI, scintigraphy, SPECT, PET Györgyi Műzes
Medical imaging X-ray, CT, MRI, scintigraphy, SPECT, PET Györgyi Műzes Semmelweis University, 2nd Dept. of Medicine Medical imaging: definition technical process of creating visual representations about
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationPOSITRON EMISSION TOMOGRAPHY (PET)
Status Active Medical and Behavioral Health Policy Section: Radiology Policy Number: V-27 Effective Date: 08/27/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationSensitivity and Specificity in Detection of Labral Tears with 3.0-T MRI of the Shoulder
Magee and Williams MRI for Detection of Labral Tears Musculoskeletal Imaging Clinical Observations C M E D E N T U R I C L I M G I N G JR 2006; 187:1448 1452 0361 803X/06/1876 1448 merican Roentgen Ray
More informationAmerican College of Radiology ACR Appropriateness Criteria
American College of Radiology ACR Appropriateness Criteria Date of origin: 1998 Last review date: 2005 Clinical Condition: Variant 1: Initial imaging test following detection of primary tumor. CT abdomen
More informationAn Unexpected Cause of Hypoglycemia
An Unexpected Cause of Hypoglycemia Stacey A. Milan, MD FACS Surgical Oncology Nothing to disclose Disclosures Objectives Identify indications for workup of hypoglycemia Define work up for hypoglycemic
More informationCT Contrast Protocols for Different Organ Imaging
CT Contrast Protocols for Different Organ Imaging g Paul Shreve, M.D. Advanced Radiology Services, P.C. & Spectrum Health Grand Rapids, MI, USA Correlative Imaging Council Society of Nuclear Medicine 56
More informationUpdate on RECIST and Staging of Common Pediatric Tumors Ethan A. Smith, MD
Update on RECIST and Staging of Common Pediatric Tumors Ethan A. Smith, MD Section of Pediatric Radiology C.S. Mott Children s Hospital University of Michigan ethans@med.umich.edu Disclosures No relevant
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationEffective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide
European Journal of Endocrinology (2003) 149 479 483 ISSN 0804-4643 CASE REPORT Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationTumori Neuroendocrini - Imaging perioperatorio. Annibale Versari Medicina Nucleare, Az.Osp. S.Maria Nuova-IRCCS - Reggio Emilia
Tumori Neuroendocrini - Imaging perioperatorio Annibale Versari Medicina Nucleare, Az.Osp. S.Maria Nuova-IRCCS - Reggio Emilia Imaging medico-nucleare=imaging molecolare Le immagini sono espressione delle
More informationStaging Colorectal Cancer
Staging Colorectal Cancer CT is recommended as the initial staging scan for colorectal cancer to assess local extent of the disease and to look for metastases to the liver and/or lung Further imaging for
More informationEUS FNA NEUROENDOCRINE TUMORS. A. Ginès Endocopy Unit Hospital Cínic. Barcelona (Spain)
EUS FNA NEUROENDOCRINE TUMORS A. Ginès Endocopy Unit Hospital Cínic. Barcelona (Spain) GI NEUROENDOCRINE TUMORS GENERAL CONCEPTS Rare neoplasms arising from the neuroendocrine cells of the GI tract Include:
More informationDisclosures. Diffusion and Perfusion Imaging in the Head and Neck. Learning objectives ???
Disclosures No relevant financial disclosures Diffusion and Perfusion Imaging in the Head and Neck Ashok Srinivasan, MD Associate Professor Director of Neuroradiology University of Michigan Health System
More informationTitle: What is the role of pre-operative PET/PET-CT in the management of patients with
Title: What is the role of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis? Pablo E. Serrano, Julian F. Daza, Natalie M. Solis June
More informationTheranostics in Nuclear Medicine
Theranostics in Nuclear Medicine Patrick FLAMEN, MD, PhD Head Nuclear Medicine Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) n Theranostics in Nuclear Medicine n A form of (nuclear) diagnostic
More informationClinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
More informationBreast Cancer PET/CT Imaging Protocol
Breast Cancer PET/CT Imaging Protocol Scanning Protocol: Patients are scanned from the top of the neck through the pelvis. Arms-up position is used to avoid beam-hardening artifact in the chest and abdomen.
More informationPET-CT for radiotherapy planning in lung cancer: current recommendations and future directions
PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions Gerry Hanna Centre for Cancer Research and Cell Biology Queen s University of Belfast @gerryhanna Talk Outline
More informationAccuracy of SPECT bone scintigraphy in diagnosis of meniscal tears ABSTRACT
1 Iran J Nucl Med 2005; 23 Accuracy of SPECT bone scintigraphy in diagnosis of meniscal tears M. Saghari 1, M. Moslehi 1, J. Esmaeili 2, M.N. Tahmasebi 3, A. Radmehr 4, M. Eftekhari 1,2, A. Fard-Esfahani
More informationDifferences in Biodistribution Between
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS Volume 20, Number 2, 2005 Mary Ann Liebert, Inc. Differences in Biodistribution Between 99m Tc-Depreotide, 111 In-DTPA-Octreotide, and 177 Lu-DOTA-Tyr 3 -Octreotate
More informationThyroid Cancer. With 51 Figures and 30 Tables. Springer
H.-J. Biersack F. Griinwald (Eds.) Thyroid Cancer With 51 Figures and 30 Tables Springer PART 1 Basics 1 The Changing Epidemiology of Thyroid Cancer 3 R. GORGES 1.1 Basic Epidemiological Problems in Thyroid
More informationThyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma.
ORIGINAL ARTICLE Thyroid remnant volume and Radioiodine ablation in Differentiated thyroid carcinoma. Md. Sayedur Rahman Miah, Md. Reajul Islam, Tanjim Siddika Institute of Nuclear Medicine & Allied Sciences,
More informationIn patients with. gastroenteropancreatic. neuroendocrine neoplasms, SSTR subtyping may help to. predict the clinical outcome. following somatostatin
In patients with gastroenteropancreatic neuroendocrine neoplasms, SSTR subtyping may help to predict the clinical outcome following somatostatin analog therapy. Annie Toja. Mediterranean Fishing Boats.
More informationReproducibility of Uptake Estimates in FDG PET: a Monte Carlo study
Reproducibility of Uptake Estimates in FDG PET: a Monte Carlo study Juliette Feuardent, Marine Soret, Irène Buvat 1 Abstract Tumor glucose metabolism measurements from Fluoro-deoxyglucose (FDG) Positron
More informationBiases affecting tumor uptake measurements in FDG-PET
Biases affecting tumor uptake measurements in FDG-PET M. Soret, C. Riddell, S. Hapdey, and I. Buvat Abstract-- The influence of tumor diameter, tumor-tobackground activity ratio, attenuation, spatial resolution,
More informationLiver imaging takes a step forward with Ingenia
Publication for the Philips MRI Community ISSUE 49 2013 / 2 Liver imaging takes a step forward with Ingenia Lyon South Hospital strives to move from several studies first CT, then MR or PET to using just
More informationCASE 1 11/1/2016 HEPATOBILIARY IMAGING CASE PRESENTATIONS DECLARATION. Dr. Chirag Patel ORGAN IMAGING yr old lady
HEPATOBILIARY IMAGING CASE PRESENTATIONS DECLARATION No financial disclosures or affiliations with commercial organisations No discussion of investigational or off-label use of medical devices, products
More informationProf. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.
Role of Whole-body Diffusion MR in Detection of Metastatic lesions Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C. Cancer is a potentially life-threatening disease,
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationNeuroendocrine Tumor of Unknown Primary Accompanied with Stomach Adenocarcinoma
J Gastric Cancer 2011;11(4):234-238 http://dx.doi.org/10.5230/jgc.2011.11.4.234 Case Report Neuroendocrine Tumor of Unknown Primary Accompanied with Stomach Adenocarcinoma Ho-Yeun Kim, Sung-Il Choi 1,
More information